Pharma / Biotech

Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.

Related Articles

Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy.

Yonsei Med J. 2020 Apr;61(4):273-283

Authors: Li Q

The reduction of survival motor neuron (SMN) protein causes spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disease. Nusinersen is an antisense oligonucleotide, approved by the FDA, which specifically binds to the repressor within SMN2 exon 7 to enhance exon 7 inclusion and augment production of functional SMN protein. Nusinersen is the first new oligonucleotide-based drug targeting the central nervous system for the treatment of SMA. This review of nusinersen will discuss its action mechanism, cellular uptake, trafficking mechanisms, and administration approaches to cross the blood-brain barrier. Furthermore, nusinersen clinical trials will be assessed in terms of pharmacokinetics, tolerability and safety, the clinical outcomes of multiple intrathecal doses, and a discussion on the primary and secondary endpoints.

PMID: 32233169 [PubMed – in process]

Source link

Related posts

Botany, traditional uses, phytochemistry, pharmacology and toxicology of Ilex pubescens Hook et Arn.


CARISOPRODOL Tablet [A-S Medication Solutions]


The Year in Drug Approvals: Specialty Still Leads the Pack


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World